LAS VEGAS, NV / ACCESSWIRE / October 18, 2023 / Odyssey Health, Inc. (OTCQB:ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products is providing an update on its Asset Purchase Agreement with Oragenics, Inc. (NYSE: OGEN).

LAS VEGAS, NV / ACCESSWIRE / October 4, 2023 / Odyssey Health, Inc. (formerly known as Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), is a medical device and pharmaceutical company with a focus on life-enhancing medical solutions, today announced that its stock has commenced trading on the OTCQB Market ("OTCQB") after successfully up-listing from the OTC Pink Market.

Gains Nasal Delivery Technologies and Expands Product Pipeline

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) and Odyssey Health, Inc. (OTCQB: ODYY ) (“Odyssey”) announce the signing of a definitive agreement under which Oragenics will acquire Odyssey’s assets related to its proprietary neurological drug therapies and technologies. The assets include drug candidates for treating mild traumatic brain injury (mTBI), also known as concussion, and for treating Niemann Pick Disease Type C (NPC), as well as Odyssey’s proprietary powder formulation and its nasal delivery device. Odyssey will retain its other assets and operations.

LAS VEGAS, NV / ACCESSWIRE / August 23, 2023 / Odyssey Health, Inc. (OTC:ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, recently presented at the Military Health System Research Symposium (MHSRS). Odyssey is developing a novel pharmaceutical, ONP-002, to be given intranasally for brain-targeted delivery in the acute through subacute period following mild traumatic brain injury (mTBI) also known as a concussion. MHSRS requested presentation submissions and after review, selected the Odyssey ONP-002 technology to be presented in poster-style at its yearly conference

LAS VEGAS, NV / ACCESSWIRE / June 8, 2023 / Odyssey Health, Inc. (OTCQB:ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, recently presented at the Special Operations Medical Association (SOMA) - Scientific Assembly. Odyssey is developing a novel pharmaceutical, ONP-002 to be given intranasally for brain-targeted delivery in the acute through subacute period following mild traumatic brain injury (mTBI) aka concussion. SOMA requested presentation submissions and after review, they selected the Odyssey ONP-002 technology to be presented in poster-style at its yearly conference.